AstraZeneca’s Forxiga and Fasenra (Prefilled Syringe and Pen) Receive EU CHMP’s Positive Opinion for CV Outcomes in T2D and Asthma

 AstraZeneca’s Forxiga and Fasenra (Prefilled Syringe and Pen) Receive EU CHMP’s Positive Opinion for CV Outcomes in T2D and Asthma

AstraZeneca’s Forxiga and Fasenra (Prefilled Syringe and Pen) Receive EU CHMP’s Positive Opinion for CV Outcomes in T2D and Asthma

Shots:

  • The positive CHMP opinion of Forxiga (dapagliflozin) follows P-III DECLARE-TIMI 58 study evaluating the CV outcomes in 17,000+ patients with T2D across 33 countries resulted in reduction in hospitalization for HF or CV death
  • The positive CHMP opinion of Fasenra (prefilled syringe and auto-injector pen) follows P-III GREGALE and GRECO & P-I AMES study evaluating the prefilled syringe & auto-injector device in patients with severe, uncontrolled asthma
  • Forxiga is a SGLT2 inhibitor, indicated as both monothx. & combination therapy for impoving glycaemic control as an adjunct to diet and exercise in adults with T2D and is under regulatory review in the US, China & Japan. Fasenra (benralizumab) is a mAb targeting IL-5 receptor alpha on eosinophils with its anticipated FDA’s approval in H2’19

Click here, Click here to read full press release/ article | Ref: AstraZeneca | Image: Philadelphia Inquirer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post